Twenty-one cases (31.8%) were classified as astrocytoma, IDH mutant, WHO grade 2, followed by WHO grade 4 (13 cases, 19.69%) and WHO grade 3 (nine cases, 13.6%). This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).